Novartis Pharma Bangladesh Valsartan brands are not affected by recall
Novartis Pharma valsartan brands Diovan®, CoDiovan®, Entresto® and Exforge® are not affected for recent recall
Dhaka, July 24, 2018: Novartis (Bangladesh) Limited, the leading multinational pharmaceutical company in Bangladesh announced that their valsartan brands - Diovan®, CoDiovan®, Entresto® and Exforge® are not affected for recent Valsartan recall.
Novartis wants to assure general public, healthcare professionals and other concerned stakeholders that the valsartan brands- Diovan®, CoDiovan®, Entresto® and Exforge®, marketed in Bangladesh, are produced using its own research based ‘innovator valsartan’ API, which is not affected.
Novartis produces its research based API for Valsartan only at its own manufacturing plants based in Switzerland and England, maintaining the highest level of quality.
Recent recall of valsartan is being done in 23 countries because an impurity was found during qualification tests of generic valsartan API (Active Pharmaceutical Ingredient) were manufactured by a certain Chinese third party manufacturer. The impurity was identified as N-Nitrosodimethylamine (NDMA).
Being a leader in pharmaceutical industry, Novartis is committed to ensuring that all our marketed products meet the highest quality standards, which is reflected in their 45 years journey in Bangladesh. Novartis wants to reassure its stakeholders that the physicians and patients can use the mentioned medicines confidently.
About Novartis (Bangladesh) Ltd.
Novartis (Bangladesh) Limited operates as a subsidiary of Novartis AG, a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Novartis (Bangladesh) Limited is a joint venture between Novartis AG (60%) and Bangladesh Chemical Industries Corporation (40%) of Government of People's Republic of Bangladesh. The company provides healthcare solutions specializing in research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Novartis operates businesses with global scale and strong customer ties, focusing on innovative patented medicines, generics and eye care devices. The Company exports its products to more than 55 countries in Europe, Asia, Africa and Latin America.